Skip to main content
    N

    Neumora Therapeutics, Inc. (NMRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.37
    -0.06 (-13.85%)

    Market Cap: $80.59M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Neumora Therapeutics, Inc. (NMRA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Neumora Therapeutics (NMRA) to earn -$0.87 per share in the fiscal year ending Dec 31, 2026. Of 9 analysts, 7 rate the stock Buy or Strong Buy, 1 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 9 ratings average 2.22, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 78% of the ratings.

    RatingAnalystsShare
    Strong Buy222.2%
    Buy555.6%
    Hold111.1%
    Sell00.0%
    Strong Sell111.1%
    Consensus
    Buy
    Total analysts
    9

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$0.87
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$0.61
    EPS consensus
    Next report
    Nov 19, 2026
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.87-$0.94 to -$0.657
    Dec 31, 2027-$0.61-$0.88 to -$0.337

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.18-$0.20 to -$0.1410

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.91.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.87-$0.86-$0.87-$0.87-$0.91N/A
    Fiscal year ending Dec 31, 2027-$0.61-$0.65-$0.67-$0.67-$0.73N/A

    Frequently Asked Questions About NMRA

    What is the NMRA stock forecast?

    Consensus analyst estimates put Neumora Therapeutics's EPS at -$0.87 for the fiscal year ending Dec 31, 2026. The consensus rating from 9 analysts is Buy.

    How do analysts rate NMRA stock?

    Of 9 analysts covering Neumora Therapeutics, 2 rate it Strong Buy, 5 Buy, 1 Hold, 0 Sell and 1 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from NMRA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.87, with estimates from -$0.94 to -$0.65 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.61, with estimates from -$0.88 to -$0.33 from 7 analysts.

    How many analysts cover NMRA?

    9 analysts rate Neumora Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.